Navigation Links
Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
Date:12/8/2009

'_blank' title='http://www.CellTherapeutics.com/investors_alert'>http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of the securities of CTI. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective for the treatment of relapsed or refractory, aggressive non-Hodgkin's lymphoma as determined by the U.S. Food and Drug Administration, the potential failure of pixantrone to significantly reduce cardiac cell toxicity compared to currently marketed anthracyclines, the potential failure of pixantrone to reintroduce an effective anthracycline like agent in patients, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.


Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: deramian@ctiseattle.com
www.CellTherapeutics.com/press_room

Investors Contact:
Ed Bell
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BD Ranked in the Top 100 Greenest Big Companies by Newsweek; Named Again to Dow Jones Sustainability World and North America Indexes
2. US Oncology, Inc. to Exhibit iKnowMed(TM) at the 2009 ASCO EHR Symposium: Harnessing the EHR: From Incentives to Sustainability
3. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
4. FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
5. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
6. Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
7. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
8. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
9. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
10. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
11. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... are living a connected life in a connected world. Our ... we will be able to connect our glasses, watch, thermostat, ... been valued by Frost & Sullivan at over $700 billion ... this change to stay ahead of the rapidly evolving world ... congress include a groundbreaking keynote address showcasing global leadership in ...
(Date:4/27/2015)... , April 27, 2015 Techpool Bio-Pharma Co ... the leadership of its new chief executive officer, transforming from ... Before Henry Lee took office in 2011, ... the pharmaceutical field, including Novartis and Eisai, with more than ... and the Asia-Pacific region. ...
(Date:4/27/2015)... 2015  MiMedx Group, Inc. (NASDAQ: MDXG ... amniotic tissue and patent-protected processes to develop and ... Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and ... results for the first quarter of 2015. ... decision of its Board of Directors to authorize ...
Breaking Medicine Technology:Frost & Sullivan's GIL 2015 Unveils the $700 Billion Connected Life Market 2Frost & Sullivan's GIL 2015 Unveils the $700 Billion Connected Life Market 3Techpool Transforms Into International Player 2Techpool Transforms Into International Player 3MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 2MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 3MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 4MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 5MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 6MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 7MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 8MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 9MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 10MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 11MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 12MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 13MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 14
... NORTH WALES, Pa., Feb. 16, 2011 AirPal, a ... received notification of allowance from the U.S. Patent Office ... position patients for situations such as difficult airway management, ... The company, founded in 1982, now holds more than ...
... and Willkie Farr & Gallagher will host an anti-bribery ... trends on French companies operating internationally. The seminar will ... of Willkie Farr & Gallagher. Please visit www.traceinternational.org ... event or contact king@traceinternational.org French ...
Cached Medicine Technology:AirPal Receives Patent for Inflatable Patient Positioning Systems 2TRACE and Willkie Farr Announce Anti-Bribery Seminar in Paris 2
(Date:4/27/2015)... 2015 UC Davis investigators have ... of an inherited disorder that historically affected Ashkenazi ... in other populations of Semitic descent, particularly families ... elegant experiments, the researchers uncovered the biochemical underpinnings ... is an incurable and progressively fatal neurological condition. ...
(Date:4/27/2015)... April 27, 2015 Based in the ... is one of the few insurance marketing organizations in ... income and asset protection markets as well as employer ... has afforded Secura Consultants the opportunity to consult with ... doing business easier and quicker. , An example of ...
(Date:4/27/2015)... On April 16, 2015, Harper’s Bazaar Magazine, in ... Marks ,” interviewed a UK dermatologist on the causes and ... are a type of scar that reportedly affects nearly 90% ... of the elsastin and collagen in the dermis, the dense ... mark removal with the Coolbeam protocol is one of our ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 Array ... exchange technology, has announced that Lance Hood, senior director ... the fourth annual Direct-to-Consumer Health Care Marketing Summit ... by David Smith, Partner and Director of Payer Services, ... health care consumerism – through a retail/e-commerce perspective – ...
(Date:4/27/2015)... Philadelphia, PA (PRWEB) April 27, 2015 Ticket ... presale tickets in Philadelphia for his upcoming concert on ... The Beatles, will thrill his countless North American fans again ... in conjunction with his "Out There" tour. He will ... will be able to listen to this legendary performer for ...
Breaking Medicine News(10 mins):Health News:UC Davis Makes Breakthrough in Understanding Canavan Disease 2Health News:UC Davis Makes Breakthrough in Understanding Canavan Disease 3Health News:UC Davis Makes Breakthrough in Understanding Canavan Disease 4Health News:Simplified Solutions Now Makes Disability Insurance Business With Secura Consultants Even Easier! 2Health News:Stretch Marks: The Latest Treatment Options for Stretch Mark Removal 2Health News:Array Health’s Senior Director of Marketing to Present at The Fourth Annual Direct-to-Consumer Health Care Marketing Summit 2Health News:Paul McCartney Presale Tickets at Wells Fargo Center in Philadelphia: Ticket Down Slashes Paul McCartney Ticket Prices in Philadelphia at the Wells Fargo Center 2
... ... Letters—for Temperature, Humidity and other Controlled Environments” , ... (Vocus) April 29, 2010 -- ... and other Controlled Environments” is now available from Veriteq ( www.veriteq.com ), ...
... beneficial, researchers say , THURSDAY, April 29 (HealthDay News) ... deep brain stimulation surgery in addition to treatment with ... the procedure, patients who underwent the surgery reported better ... and engage in routine daily activities compared to those ...
... , ... is a saying that seems to ring true according to husbands whose wives have had ... Surgery takes a look at the transformative journey from the husband,s perspective. , ... Newport Beach, Calif (Vocus) April 29, 2010 ...
... ... NeverTouch® laser fiber , ... Albany, N.Y. (PRWEB) April 29, 2010 -- AngioDynamics (NASDAQ: ANGO) announced today that ... expected to be featured in a segment on the popular television show "The Doctors.", ...
... ... of pool security results in the death of 100’s of children around the world. Despite it ... posing a serious risk. , ... 29, 2010 -- Du Toit & Associates plead to all swimming pool owners to follow swimming ...
... ... Awareness of Symptoms of Brain Aneurysms , ... Boston, MA (PRWEB) April 29, 2010 - On April 23, ... Seventy to eighty percent of spontaneous subarachnoid hemorrhages are caused by ruptured cerebral ...
Cached Medicine News:Health News:Guide for US FDA-Regulated Organizations Now Available 2Health News:Guide for US FDA-Regulated Organizations Now Available 3Health News:Adding Surgery to Meds May Improve Life With Parkinson's 2Health News:Cruise Plastic Surgery Looks at Mommy Makeovers from the Husband's Perspective and Offers Tips 2Health News:Cruise Plastic Surgery Looks at Mommy Makeovers from the Husband's Perspective and Offers Tips 3Health News:Cruise Plastic Surgery Looks at Mommy Makeovers from the Husband's Perspective and Offers Tips 4Health News:AngioDynamics' VenaCure EVLTTM System for Varicose Veins To Be Featured On 'The Doctors' National Television Program 2Health News:AngioDynamics' VenaCure EVLTTM System for Varicose Veins To Be Featured On 'The Doctors' National Television Program 3Health News:AngioDynamics' VenaCure EVLTTM System for Varicose Veins To Be Featured On 'The Doctors' National Television Program 4Health News:Du Toit & Associates Prepare to Prevent Silent Deaths by the Pool this Summer 2Health News:Early Detection Makes a Difference in the Treatment of Brain Aneurysms 2Health News:Early Detection Makes a Difference in the Treatment of Brain Aneurysms 3
... specifically formulated for high resolution of small ... This standard melting temperature agarose can resolve ... bp difference in size. UltraPure™ Agarose ... for better handling and improved clarity for ...
... low electroendosmosis (EEO) is ... applications. If separated nucleic ... used as substrates for ... restriction endonucleases, a special ...
Excellent multi purpose agarose Nuclease-free, Gel point (1.5%): 36 1.5 C, EEO: 0.05-0.13 Gel strength (1%): > 1200 g/cm 2 ....
... is a standard gelling temperature, high gel ... than 1,000 bp. This Genetic Technology Grade™ ... DNA electrophoresis. DNA recovered from SeaKem GTG ... ligated. SeaKem GTG Agarose is extensively performance ...
Medicine Products: